Negative Prognostic Associations of Selective Serotonin Reuptake Inhibitors Use in Hospitalized COVID-19 Patients and Potential Contribution of Cardiovascular Comorbidities
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Selective serotonin reuptake inhibitors (SSRIs) were associated with increased mortality and respiratory deterioration in hospitalized COVID-19 patients. This study contradicts earlier suggestions of SSRI protection against SARS-CoV-2 infection.
Area Of Science
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Background
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a contagious respiratory illness.
- Emerging evidence challenges prior notions that selective serotonin reuptake inhibitors (SSRIs) may offer protection during SARS-CoV-2 infection.
Purpose Of The Study
- To investigate the association between SSRI use and clinical outcomes in hospitalized COVID-19 patients.
- To re-evaluate the potential protective role of SSRIs in the context of severe COVID-19.
Main Methods
- Retrospective evaluation of a tertiary referral center's institutional registry.
- Analysis of SSRI use and clinical outcomes in 1,558 hospitalized COVID-19 patients, focusing on severe and critical cases.
Main Results
- SSRI use was linked to significantly higher risks of death, mechanical ventilation, ICU admission, and bacteremia.
- No significant association was found between SSRI use and risks of thrombosis or major bleeding.
- Certain patient subgroups, including those with less severe initial presentation and specific comorbidities, showed higher mortality with SSRI use.
Conclusions
- Findings support an association between SSRI use and increased mortality in hospitalized COVID-19 patients.
- SSRI use may also correlate with heightened risks of respiratory decline, ICU admission, and bacteremia.
- Cardiovascular comorbidities might contribute to adverse outcomes in SSRI-exposed COVID-19 patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Chronic stress profoundly affects mental health, significantly influencing mood, behavior, and overall quality of life. Research closely links chronic stress with mental health conditions such as depression, anxiety, and substance use disorders. Ongoing exposure to stress can lead to physiological and psychological changes, initiating a cycle of emotional distress and maladaptive coping mechanisms.
Individuals with depression often experience challenges in both their personal and professional...